Changes in Lysophospholipid Components in Ulcerative Colitis and Colitis-associated Cancer.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
May 2022
Historique:
received: 14 02 2022
revised: 13 03 2022
accepted: 17 03 2022
entrez: 30 4 2022
pubmed: 1 5 2022
medline: 4 5 2022
Statut: ppublish

Résumé

In recent years, it has become clear that, in addition to normal cytokines, phospholipid mediators play an important role in the development, growth, infiltration, and metastasis of cancer and in the cancer microenvironment. A phospholipid analysis method using tandem mass spectrometry (LC-MS/MS) with high detection sensitivity has enabled quantification of phospholipids, even when using a very small sample. To date, we had applied this MS technology to colorectal cancer tissue. Therefore, in this study, this mass spectrometry technique was applied to ulcerative colitis (UC) and UC-related colorectal cancer, and an analysis was conducted with the aim of clarifying which lysophospholipids specifically change in each type of tissue. UC-associated colorectal cancer tissue and UC mucosa were collected from surgical specimens of colitic cancer (n=3). Cancerous and non-cancerous tissues were collected from surgical specimens from patients with sporadic colorectal cancer (n=11). After extraction from these tissues, the amounts of lysophospholipids were quantified by LC-MS/MS. In addition, lysophosphatidylserine (LPS) and lysophosphatidylinositol (LPI) were quantified for each molecular species of fatty acids. Compared to normal mucosa, LPI was increased 3.8-fold (p<0.001) and LPS 3.5-fold (p<0.001) in UC-related colorectal cancer. Molecular species of LPI which were increased in UC-related colorectal cancer were 18:0 (p=0.001), 16:0 (p=0.03) and 20:4 (p=0.004), and of LPS were 18:0 (p<0.001) and 22:6 (p=0.014). Lysophospholipids increased in colorectal cancer and in UC-associated colorectal cancer. In particular, LPI may have contributed significantly to colitis-associated carcinogenesis.

Sections du résumé

BACKGROUND BACKGROUND
In recent years, it has become clear that, in addition to normal cytokines, phospholipid mediators play an important role in the development, growth, infiltration, and metastasis of cancer and in the cancer microenvironment. A phospholipid analysis method using tandem mass spectrometry (LC-MS/MS) with high detection sensitivity has enabled quantification of phospholipids, even when using a very small sample. To date, we had applied this MS technology to colorectal cancer tissue. Therefore, in this study, this mass spectrometry technique was applied to ulcerative colitis (UC) and UC-related colorectal cancer, and an analysis was conducted with the aim of clarifying which lysophospholipids specifically change in each type of tissue.
MATERIALS AND METHODS METHODS
UC-associated colorectal cancer tissue and UC mucosa were collected from surgical specimens of colitic cancer (n=3). Cancerous and non-cancerous tissues were collected from surgical specimens from patients with sporadic colorectal cancer (n=11). After extraction from these tissues, the amounts of lysophospholipids were quantified by LC-MS/MS. In addition, lysophosphatidylserine (LPS) and lysophosphatidylinositol (LPI) were quantified for each molecular species of fatty acids.
RESULTS RESULTS
Compared to normal mucosa, LPI was increased 3.8-fold (p<0.001) and LPS 3.5-fold (p<0.001) in UC-related colorectal cancer. Molecular species of LPI which were increased in UC-related colorectal cancer were 18:0 (p=0.001), 16:0 (p=0.03) and 20:4 (p=0.004), and of LPS were 18:0 (p<0.001) and 22:6 (p=0.014).
CONCLUSION CONCLUSIONS
Lysophospholipids increased in colorectal cancer and in UC-associated colorectal cancer. In particular, LPI may have contributed significantly to colitis-associated carcinogenesis.

Identifiants

pubmed: 35489747
pii: 42/5/2461
doi: 10.21873/anticanres.15724
doi:

Substances chimiques

Lipopolysaccharides 0
Lysophospholipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2461-2468

Informations de copyright

Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Hirofumi Sonoda (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan; sonodah-sur@h.u-tokyo.ac.jp.

Chieko Kitamura (C)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Kuniyuki Kano (K)

Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.

Hiroyuki Anzai (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Yuzo Nagai (Y)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Shinya Abe (S)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Yuichiro Yokoyama (Y)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Hiroaki Ishii (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Junko Kishikawa (J)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Koji Murono (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Shigenobu Emoto (S)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Kazuhito Sasaki (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Kazushige Kawai (K)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Hiroaki Nozawa (H)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Junken Aoki (J)

Department of Health Chemistry, Graduate School of Pharmaceutical Sciences, University of Tokyo, Tokyo, Japan.

Soichiro Ishihara (S)

Department of Surgical Oncology, The University of Tokyo, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH